Cargando…
Heart Failure Therapies for the Prevention of HER2-Monoclonal Antibody-Mediated Cardiotoxicity: A Systematic Review and Meta-Analysis of Randomized Trials
SIMPLE SUMMARY: Monoclonal antibodies targeting HER2 are used for the management of early and metastatic HER2-positive breast cancer. Approximately 10–15% of patients diagnosed with breast cancer will be HER2-positive. The incidence of heart failure in breast cancer patients is becoming increasingly...
Autores principales: | Brown, Lauren J., Meredith, Thomas, Yu, Jie, Patel, Anushka, Neal, Bruce, Arnott, Clare, Lim, Elgene |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583665/ https://www.ncbi.nlm.nih.gov/pubmed/34771689 http://dx.doi.org/10.3390/cancers13215527 |
Ejemplares similares
-
Cardiotoxicity Surveillance and Risk of Heart Failure During HER2 Targeted Therapy
por: Yu, Anthony F., et al.
Publicado: (2020) -
Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis
por: Alhussein, Muhammad Mustafa, et al.
Publicado: (2021) -
Examining Cardiotoxicity With HER2 Therapies
por: Denduluri, Neelima
Publicado: (2020) -
Systematic Review: Monoclonal Antibody-Induced Subacute Cutaneous Lupus Erythematosus
por: Bolton, Chrissy, et al.
Publicado: (2020) -
Cardioprotective Agents for the Primary Prevention of Trastuzumab-Associated Cardiotoxicity: A Systematic Review and Meta-Analysis
por: Goulas, Kyriakos, et al.
Publicado: (2023)